Compare Stocks: RGC, CORT, AXSM, and RDY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$212.74 +1.2%	$236.95	$102.67 ▼ $260.19	$10.95B	0.65	678,187 shs	1.02 million shs
CORT Corcept Therapeutics	$110.77 +2.6%	$89.31	$28.66 ▼ $122.21	$11.97B	0.45	1.40 million shs	769,035 shs
RDY Dr. Reddy's Laboratories	$12.22 +0.9%	$13.17	$11.36 ▼ $15.67	$10.20B	0.29	2.88 million shs	2.56 million shs
RGC Regencell Bioscience	$5.41 -0.9%	$10.13	$4.51 ▼ $69.00	$2.68B	1.88	264,921 shs	191,414 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	0.00%	-2.41%	-14.55%	-2.13%	+106.02%
CORT Corcept Therapeutics	0.00%	-3.25%	+18.79%	+111.88%	+57.08%
RDY Dr. Reddy's Laboratories	0.00%	+3.12%	-12.03%	-7.81%	-8.54%
RGC Regencell Bioscience	0.00%	-12.46%	-10.87%	-81.52%	-57.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$212.74 +1.2%	$236.95	$102.67 ▼ $260.19	$10.95B	0.65	678,187 shs	1.02 million shs
CORT Corcept Therapeutics	$110.77 +2.6%	$89.31	$28.66 ▼ $122.21	$11.97B	0.45	1.40 million shs	769,035 shs
RDY Dr. Reddy's Laboratories	$12.22 +0.9%	$13.17	$11.36 ▼ $15.67	$10.20B	0.29	2.88 million shs	2.56 million shs
RGC Regencell Bioscience	$5.41 -0.9%	$10.13	$4.51 ▼ $69.00	$2.68B	1.88	264,921 shs	191,414 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	0.00%	-2.41%	-14.55%	-2.13%	+106.02%
CORT Corcept Therapeutics	0.00%	-3.25%	+18.79%	+111.88%	+57.08%
RDY Dr. Reddy's Laboratories	0.00%	+3.12%	-12.03%	-7.81%	-8.54%
RGC Regencell Bioscience	0.00%	-12.46%	-10.87%	-81.52%	-57.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.91	Moderate Buy	$265.55	24.82% Upside
CORT Corcept Therapeutics	2.63	Moderate Buy	$119.17	7.58% Upside
RDY Dr. Reddy's Laboratories	1.67	Reduce	N/A	N/A
RGC Regencell Bioscience	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest RGC, CORT, AXSM, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$310.00 ➝ $306.00
7/30/2026	CORT Corcept Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$95.00 ➝ $165.00
7/30/2026	CORT Corcept Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$88.00 ➝ $165.00
7/29/2026	CORT Corcept Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $150.00
7/27/2026	CORT Corcept Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Peer Perform ➝ Underperform	$50.00
7/23/2026	RDY Dr. Reddy's Laboratories	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/20/2026	AXSM Axsome Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$310.00
7/20/2026	AXSM Axsome Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/20/2026	AXSM Axsome Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/17/2026	AXSM Axsome Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$290.00

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$708.24M	15.46	N/A	N/A	$1.75 per share	121.57
CORT Corcept Therapeutics	$761.41M	15.73	$0.90 per share	122.70	$6.53 per share	16.96
RDY Dr. Reddy's Laboratories	$331.19B	0.03	$0.85 per share	14.43	$4.90 per share	2.49
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.73	N/A	52.40	N/A	-26.59%	-267.16%	-28.53%	8/10/2026 (Estimated)
CORT Corcept Therapeutics	$99.65M	$0.42	263.74	47.14	N/A	6.52%	8.26%	6.45%	N/A
RDY Dr. Reddy's Laboratories	$456M	$0.44	27.76	20.70	2.45	10.15%	9.49%	6.32%	10/23/2026 (Estimated)
RGC Regencell Bioscience	-$3.58M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest RGC, CORT, AXSM, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	N/A	N/A	N/A	$221.11 million	N/A
7/29/2026	Q2 2026	CORT Corcept Therapeutics	$0.0243	$0.36	+$0.3357	$0.36	$221.15 million	$256.15 million
7/23/2026	Q1 26/27	RDY Dr. Reddy's Laboratories	$0.0918	$0.06	-$0.0318	$0.06	$850.56 million	$850.26 million
5/12/2026	Q4 25/26	RDY Dr. Reddy's Laboratories	$0.09	$0.06	-$0.03	-$0.03	$886.58 million	$852.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.49%	+6.96%	13.64%	N/A
RGC Regencell Bioscience	$0.88	16.27%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	2.27	1.39	1.32
CORT Corcept Therapeutics	N/A	2.86	2.77
RDY Dr. Reddy's Laboratories	0.03	1.90	1.39
RGC Regencell Bioscience	N/A	1.41	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CORT Corcept Therapeutics	93.61%
RDY Dr. Reddy's Laboratories	3.85%
RGC Regencell Bioscience	0.13%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
CORT Corcept Therapeutics	20.70%
RDY Dr. Reddy's Laboratories	2.00%
RGC Regencell Bioscience	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	51.46 million	40.86 million	Optionable
CORT Corcept Therapeutics	300	108.10 million	85.72 million	Optionable
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.97 million	Optionable
RGC Regencell Bioscience	10	494.49 million	484.60 million	N/A

RGC, CORT, AXSM, and RDY Headlines

Recent News About These Companies

Regencell Bioscience (NASDAQ:RGC) Stock Price Down 7.2% - Time to Sell?

July 22, 2026 | marketbeat.com

Regencell Bioscience (NASDAQ:RGC) Trading 12% Higher - Should You Buy?

July 21, 2026 | marketbeat.com

Regencell Bioscience Posts Higher Losses in First-Half 2026 Results Filed on Form 6-K

July 3, 2026 | theglobeandmail.com

Regencell Bioscience surges on apparent short squeeze

July 1, 2026 | msn.com

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Investors Have Until June 23, 2026 to Seek a Leadership Role in the Securities Class Action Lawsuit Contact Kaplan Fox ...

June 30, 2026 | theglobeandmail.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGC

June 23, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

June 23, 2026 | prnewswire.com

Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

June 23, 2026 | businesswire.com

Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors

June 23, 2026 | globenewswire.com

RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm

June 23, 2026 | prnewswire.com

RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

June 23, 2026 | tmcnet.com

RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

June 23, 2026 | prnewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | tmcnet.com

REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role

June 22, 2026 | globenewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC)Â Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | businesswire.com

DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

June 22, 2026 | globenewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGC

June 22, 2026 | globenewswire.com

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited ...

June 21, 2026 | gazettextra.comG

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC

June 21, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

June 21, 2026 | globenewswire.com

RGC DEADLINE: The Gross Law Firm Reminds Regencell Bioscience Holdings Limited Investors of Upcoming Securities Class Action Deadline

June 19, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC, CORT, AXSM, and RDY Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$212.74 +2.61 (+1.24%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$211.84 -0.90 (-0.42%)

As of 08/7/2026 07:59 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corcept Therapeutics NASDAQ:CORT

$110.77 +2.82 (+2.61%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$111.03 +0.26 (+0.23%)

As of 08/7/2026 07:45 PM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Dr. Reddy's Laboratories NYSE:RDY

$12.22 +0.11 (+0.87%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$12.20 -0.01 (-0.08%)

As of 08/7/2026 07:34 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Regencell Bioscience NASDAQ:RGC

$5.41 -0.05 (-0.92%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$5.60 +0.19 (+3.49%)

As of 08/7/2026 07:58 PM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RGC, CORT, AXSM, and RDY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RGC, CORT, AXSM, and RDY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RGC, CORT, AXSM, and RDY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC, CORT, AXSM, and RDY Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Corcept Therapeutics NASDAQ:CORT

Dr. Reddy's Laboratories NYSE:RDY

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RGC, CORT, AXSM, and RDY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RGC, CORT, AXSM, and RDY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RGC, CORT, AXSM, and RDY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGC, CORT, AXSM, and RDY Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Corcept Therapeutics NASDAQ:CORT

Dr. Reddy's Laboratories NYSE:RDY

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools